CRISPR Therapeutics CTX112: Next-Gen CAR-T Faces September PDUFA

CRISPR Therapeutics’ CTX112 is the company’s second drug to reach a PDUFA date — and it could cement CRISPR as a multi-product company, not a one-trick Casgevy story.

The drug

CTX112 is a next-generation CAR-T cell therapy for relapsed/refractory B-cell malignancies. It uses CRISPR gene editing to knock out three genes (TRAC, B2M, PD-1) that limit CAR-T function, and knocks in a CD19-targeting CAR and a HLA-E shield to protect the cells from immune rejection.

In plain English: it’s a more durable, more potent version of first-gen CAR-T, engineered to last longer in the body and resist the tumor’s attempts to shut it down.

The data

The Phase 1 trial in 32 patients with relapsed/refractory B-cell malignancies showed:

• Overall response rate (ORR): 69%
• Complete response (CR): 59%
• 6-month durability: 82% of CR patients remained in remission at 6 months

The safety profile was manageable: cytokine release syndrome (CRS) in 22% (all Grade 1-2), no Grade 3+ neurotoxicity. No dose-limiting toxicities.

The FDA granted Fast Track designation based on this data. The PDUFA date is September 12.

The market

CAR-T cell therapies are a $5 billion market, growing 20%+ per year. Current leaders:

• Gilead (Yescarta): ~$1.5B revenue, CD19 CAR-T for lymphoma
• Novartis (Kymriah): ~$0.5B revenue, CD19 CAR-T for leukemia/lymphoma
• J&J/BMS (Carvykti): ~$1B revenue, BCMA CAR-T for myeloma

CTX112 enters the CD19 CAR-T market, competing with Yescarta and Kymriah. The differentiator: enhanced potency from CRISPR editing, potentially better durability, and an “off-the-shelf” (allogeneic) manufacturing approach that doesn’t require collecting the patient’s own cells.

If approved, peak sales estimates range from $500M–$1.5B. CRISPR Therapeutics’ market cap is $7.5B, driven by Casgevy (sickle cell) and this pipeline.

What we’re watching

1. September 12 PDUFA: Approval expected. The question is label breadth — will the FDA approve for all B-cell malignancies or limit to specific indications?
2. October 10 AdCom: The CTGTAC will review manufacturing consistency for the allogeneic platform. If the committee raises concerns, it could delay approval.
3. Phase 2 data: CRISPR is running a larger trial to support label expansion. Data expected in 2027.
4. Solid tumor program: CTX131 (CAR-T for solid tumors) is the bigger pipeline story. Phase 1 data in Q4 2026.

CRISPR Therapeutics is building a multi-product company on the gene-editing platform. CTX112 is the second proof point.